This entity is distinct from chronic pancreatitis and classic AIP due to its largely asymptomatic presentation.4 ICI-PI is more common with ICIs targeting CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) compared with those targeting PD-1, and the risk is highest in combination therapy.5 This evidence concerns the gene CTLA4 and autoimmune pancreatitis.